Background: Since proteoglycans (PGs) appear as key partners in chondrosarcoma biology, PG-targeted imaging using the radiotracer 99m Tc-N-(triethylammonium)-3-propyl-[15]ane-N5 ( 99m Tc-NTP 15-5) developed by our group was previously demonstrated to be a good single-photon emission computed tomography tracer for cartilage neoplasms. We therefore initiated this new preclinical study to evaluate the relevance of 99m Tc-NTP 15-5 imaging for the in vivo monitoring and quantitative assessment of chondrosarcoma response to zoledronic acid (ZOL) in the Swarm rat orthotopic model.
Introduction
Considering the 10-year survival rate of chondrosarcoma (from 29% to 83% depending on the subtype and grading), improving its clinical management is a challenge and novel therapeutic approaches are needed [1] . This implies that in vivo markers of the biologic phenotypic features of chondrosarcoma behavior in the bone environment could be used as quantitative criteria of grading, follow-up, and early evaluation of response to therapy.
Since proteoglycans (PGs) appear as key partners in chondrosarcoma biology, PG-targeted imaging using the radiotracer 99m Tc-N-(triethylammonium)-3-propyl- [15] ane-N5 ( 99m Tc-NTP 15-5) developed by our group was expected to be a good single-photon emission computed tomography (SPECT) tracer for the molecular imaging of cartilage neoplasms in nuclear medicine [2, 3] .
Resistance to chemotherapy is well known to make chondrosarcoma therapeutic management difficult [4] . The bisphosphonate zoledronic acid (ZOL) has demonstrated its therapeutic interest in a variety of tumors affecting the bones, such as osteosarcoma, Ewing's sarcoma, and chondrosarcoma [5] [6] [7] .
This study was therefore initiated in the wellcharacterized Swarm rat chondrosarcoma (SRC) orthotopic model to determine the relevance of 99m Tc-NTP 15-5 imaging for an early quantitative characterization of chondrosarcoma response to ZOL.
Methods
Protocols were performed under the authorization of the French Directorate of Veterinary Services (Authorization No. C63-113-10) and were conducted under the supervision of authorized investigators in accordance with the institution's recommendations for the use of laboratory animals. 
Model
Experiments were conducted on 24 male Sprague Dawley rats (Charles River, L'Arbresle, France). The SRC model was a generous gift from Dr. P.A. Guerne (Switzerland) as tissue fragments, which were frozen until use. Allograft transplantation of a 10-mm 3 SRC fragment was performed on the right hindlimb in the paratibial location of the anesthetized animals (isoflurane (Abbott, Rungis, France) in air (1.5%, 1 L/min)) associated with an intramuscular injection of 100 mg/kg of ketamine (Imalgene®, Rhone Merieux, Lyon, France), as published [3, 6, 8] .
ZOL treatment
ZOL was kindly provided as a research-grade disodium salt by Novartis Pharma AG (Basel, Switzerland). Rats were randomly divided into two groups:
1. ZOL-treated: subcutaneous administration of 100 μg/kg twice a week from day 4 to day 48 after implantation (n = 12) 2. Control: PBS in the same conditions (n = 12)
Tumor growth assessment
Tumor volume was calculated from calliper measurement of the largest (L) and smallest (S) perpendicular tumor diameters, using the formula: V (mm3) = 0.5 × L × S 2 [3] . Data were expressed as mean ± standard deviation. At each time point, the tumor volumes of ZOL and controls were compared by analysis of variance (ANOVA) with a level of significance set at p < 0.05. 99m Tc-NTP 15-5 imaging 99m Tc-NTP 15-5 imaging was performed at days 4 (before treatment), 11, 16, 24, 36, and 48 after implantation. NTP 15-5 was radiolabeled with 99m Tc as described [3] .
Acquisitions (10-min duration, 15% window at 140 keV) of each hindlimb of anesthetized animals positioned over a 10-cm collimator of a small-animal gamma camera (γImager, Biospace, Paris, France) were performed, 30 min after i.v. administration of 30 MBq of radiotracer. Fixedsize regions of interest (ROIs) were delineated over the tumor, adjacent muscles, and contralateral muscles, and average counts (cpm/mm 2 ) were obtained. The use of activity profile for ROI placement ensured easy, reproducible positioning of the ROI for serial images.
At each time point and for each animal, the targetto-background ratio (TBR) was calculated as follows: TBR = Average count in the tumor (cpm/mm 2 ) / Average count in the contralateral muscle (cpm/mm 2 ). Data were expressed as mean ± standard deviation.
Analysis of data with multiple comparisons was performed by repeated-measures ANOVA followed by Tukey's post-test, with a level of significance set at p < 0.05.
Histology
At the end of the study, tumors fixed in 4% formalin were embedded in paraffin, sectioned (5 μm), and stained with hematoxylin-eosin and alcian blue (AB).
Results

ZOL inhibited tumor growth
As shown in Figure 1 , ZOL inhibited tumor growth as compared to controls: From day 24 to day 48, a significant (p < 0.05) difference in tumor volume was observed between control and treated groups. Tumor regression patterns were clearly evidenced by histology ( Figure 2 ): whereas controls showed nuclear atypia, anisokaryosis, mitosis, lobular arrangement of the tumor, and metachromasia (Figure 2A,B,C) , ZOL-treated animals demonstrated fibrous and inflammatory remodeling patterns of tumor regression ( Figure 2D,E) . Metachromasia, reflecting PG content, was also decreased in ZOL-treated animals as compared to controls ( Figure 2F versus Figure 2C ). 99m Tc-NTP 15-5 monitoring of in vivo chondrosarcoma response to ZOL As illustrated in Figure 3A , for representative animals, 99m Tc-NTP 15-5 accumulation was observed in the joints and at the sites of tumor implantation as early as day 4. As pathology evolved, a weaker radiotracer accumulation was observed in ZOL-treated tumors as compared to controls.
From day 11 to day 48, mean TBR values ranged from 1.7 ± 0.6 to 2.3 ± 0.6 in ZOL-treated rats and from 2.1 ± 1.0 to 4.9 ± 0.9 in controls ( Figure 3B ). Differences in TBR between treated rats and controls were statistically significant (p < 0.05) from day 24 to day 48. Repeatedmeasures ANOVA revealed both a significant 'betweengroup effect' as well as a within-subject effect (group * time).
Discussion
A few years ago, Heymann's group published the therapeutic relevance of using ZOL in the SRC model [6] . Since then, others have reported the promising effects of bisphosphonates not only on chondrosarcoma proliferation and invasion in vitro, but also in clinical practice [7, 9, 10] . In clinics, chondrosarcoma therapeutic response is still evaluated by conventional imaging by measuring anatomical tumor size reduction [11] . Unlike the late effects of anticancer therapy on tumor size, molecular and metabolic changes are well recognized to be induced much earlier, before morphological changes occur [12] .
Our previous study demonstrated 99m Tc-NTP 15-5 to be a promising SPECT tracer for the molecular imaging of cartilage neoplasms in nuclear medicine [3] . 99m Tc-NTP 15-5 appeared of particular interest since radiotracers currently available in clinics such as 201 Tl, 99m Tc-MIBI, 99m Tc-tetrofosmin, 99m Tc-DMSA(V), and 18 F-FDG have evidenced limitations for imaging chondrosarcoma with low cellularity and high chondrogenic matrix [13] .
The results reported in this new study bring additional data in favor of 99m Tc-NTP 15-5 imaging for the in vivo follow-up of chondrosarcoma and more especially the semi-quantitative assessment of therapeutic response in vivo, with TBR values being significantly decreased in the treated group with respect to controls from day 24. Chondrosarcoma growth inhibition was confirmed by calliper measurement from day 24 and characterized at the tissue level by histology: interestingly, AB staining evidenced a huge decrease in glycosaminoglycan content in ZOL as compared to controls. Such PG 'downregulation' reflects the tumor proliferation inhibition at the extracellular matrix level and is expected to be at the origin of the decreased accumulation of the 99m Tc-NTP 15-5 radiotracer in tumors responding to ZOL.
Conclusion
99m Tc-NTP 15-5 is expected to offer a novel imaging modality for the semi-quantitative evaluation of PG in vivo as markers of the extracellular matrix features of chondrosarcoma, which could be useful for the followup and evaluation of the response to therapeutic attempts. Combining chondrosarcoma functional imaging at the PG level with relevant targeted therapies may represent the opportunity to bridge the gap between preclinical and clinical testing, which is of real need for improving the management of this pathology.
